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CORRESPONDENCE
Letters to the Editor
The Effect of
Drug-Eluting Stents on
Collateral Coronary Flow
I read with great interest the article by Meier et al. (1) published
in the previous issue of the Journal. The article seems to report
another, previously unappreciated, adverse effect of the use of
drug-eluting stents (DES): impairment of coronary collateral
function. Despite the large study population and the elegant
well-validated method of measurement of collateral flow (2), we
remain very skeptical that this study truly proves its main conclusion.
After stent implantation, there is no stimulus for collateral
development because the main factors promoting its growth
(regional ischemia and the pressure gradient between poststenotic
artery and other normal or prestenotic coronary arterial segments)
are abolished. Conceptually, it is difficult to understand how an
extremely small amount of antiproliferative/cytotoxic medication
released downstream of the site of stent implantation can affect
quiescent endothelial cells in collapsed vessels with no flow. The
elution profile of the DES is so short that it is unconceivable to
expect a persistent drug release months after implantation, when
collateral neoformation may occur in response to severe restenosis.
A possible explanation for the difference observed and a sug-
gestion for data reanalysis comes from a more careful observation
of Figure 2: both groups seem to cluster at the bottom of the
collateral flow index range, suggesting a non-normal distribution
of the study population. Should a nonparametric test such as the
Wilcoxon signed rank test for paired data be used, the results of the
analysis could change.
The most likely reason for the high collateral flow index
observed in some patients with bare-metal stents (BMS) is the
presence of a more severe degree of restenosis in these patients.
Even though a similar average percent diameter stenosis is reported
on angiography, this is not sufficient to indicate an equivalent
functional severity in the 2 populations. The typical pattern of
in-stent restenosis after BMS implantation is diffuse proliferation,
as opposed to focal restenosis in DES, often at the edges of the
stent (3). If available, comparison of fractional flow reserve in the
2 groups at follow-up is a better marker of hemodynamic severity
(4) and would greatly help to clarify the cause of the observed
difference in collateral flow index.
Assuming that a “statistically significant” difference in collateral
flow index between the BMS and the DES groups truly exists, this
difference is unlikely to be clinically relevant. The collateral flow
index was so low in the majority of patients regardless of the type
of stent implanted, to be incompatible with myocardial viability in
the territory of distribution of the stented artery should an acute
occlusion, for instance a thrombosis, suddenly develop.
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Drug-Eluting Stent
Implantation and Coronary
Collateral Growth Attenuation:
Is Drug the Only Culprit?
In a recent issue of the Journal, Meier et al. (1) presented the
results of a physiological study designed to compare coronary flow
index in patients after bare-metal stent (BMS) or drug-eluting
stent (DES) implantation. They concluded that collateral function,
6 months after coronary stenting, with a DES is 30% to 40% lower
compared with a BMS. The authors hypothesized that their
findings might be related, in part, to the antiangiogenic properties
of DES through an inhibition of endothelial growth factors and
cytokines. Globally, reduced collateral formation may have a
negative influence on ischemic burden, particularly in the event of
acute thrombosis.
Although this study highlights a potentially new and important
downside of DES utilization, its results must be carefully analyzed
and interpreted in a broader clinical context. In fact, the patient
population selected in the DES group had a remarkably high
degree of restenosis after 6 months, as evidenced by coronary
angiographic data, showing an average of 45% in-stent diameter
stenosis in the 2 matched groups. Such a high level of restenosis 6
months after DES implantation is rarely observed in clinical
practice. Therefore, it can be hypothesized that by matching BMS
and DES patients for in-stent stenosis severity, Meier et al.
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